ASH 2020 | First-in-class IgM based CD20-CD3 bispecific antibody in B-cell NHL
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, shares the results of a Phase I first-in-human dose-escalation trial (NCT04082936) of the IGM-2323 bispecific antibody in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). The CD20-CD3 bispecific antibody uses an engineered IgM framework, such that it has 10 binding sites for CD20 and only one for CD3. It is thought this will prevent the T-cell overstimulation that causes cytokine release syndrome (CRS) seen with the use of other bispecific antibodies. Preliminary results show a promising safety and tolerability profile: there were no drug-related serious adverse events, dose-limiting toxicities, or discontinuations due to toxicity. Accrual into the dose-escalation phase is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy: AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Yingli Pharmaceuticals
Research Grants: AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem
All payments made to Sarah Cannon Research Institute, not to the physician
